These findings suggest that tumors with abundant SOX2 or CD133 positive cancer stem cells at the time of diagnosis are more sensitive to current treatments when the MGMT promoter is methylated, warranting further investigation into the potential relationships between the degree of stem cell phenotype and response to therapy. This evidence concerns the gene SOX2 and cancer.